First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma。The majority of
refractory patients have PD-L1 expression due to P53 mutations, some of which account for
about 10% of DLBCL.Our department has found that in refractory DLBCL with high PD-L1
expression, cedilizumab monotherapy is also more effective and has reversed chemotherapy
resistance.The aim of this study was to determine whether the addition of sindilizumab to the
R-CHOP regimen could improve the objective efficiency of DLBCL patients with P53 mutation
with PD-L1 expression and to see if it could prolong patient survival.